Literature DB >> 27182030

Intravenous Home Infusion Therapy Instituted From a 24-Hour Clinical Decision Unit For Patients With Cellulitis.

Manjusha Rentala1, Shari Andrews2, Allison Tiberio3, Kumar Alagappan4, Tammy Tavdy5, Patrick Sheppard6, Robert Silverman7.   

Abstract

OBJECTIVES: The objective of the study is to evaluate whether patients with cellulitis can be safely discharged from a 24-hour clinical decision unit (CDU) with home infusion of intravenous (IV) antibiotics.
METHODS: Clinical decision unit patients receiving IV antibiotics for cellulitis were screened for enrollment in a home infusion therapy (HIT) program. Inclusion criteria were patient ability and willingness to administer IV antibiotics at home and insurers' approval of home infusion services. Patients were discharged home with a peripheral IV and care coordinated with a home infusion provider.
RESULTS: Of 213 patients with cellulitis transferred from the emergency department to the CDU over an 8-month study period, a total of 32 (15%) were discharged from the CDU with HIT. The average duration of home IV antibiotic treatment was 3.4 days. There were a total of 9 complications (28%), including IV infiltration (n = 5), allergic reactions (n = 2), nontolerance to the antibiotic (n = 1, this patient developed severe nausea and was switched to oral antibiotics after 2 days of HIT), and 1 patient required readmission for lack of clinical improvement. Among the 181 patients with cellulitis who did not receive HIT, 39 (22%) were hospitalized from the CDU, and 1 additional patient refused admission.
CONCLUSIONS: We avoided admission for 31 (97%) of 32 patients who were enrolled in HIT. Home infusion therapy has the potential to prevent hospitalizations, alleviate overcrowding of hospital beds, and decrease health care costs. Further studies are needed to determine the full impact of HIT on CDU patients with acute cellulitis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27182030     DOI: 10.1016/j.ajem.2016.04.022

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  6 in total

1.  Update on management of skin and soft tissue infections in the emergency department.

Authors:  Michael S Pulia; Mary R Calderone; John R Meister; Jamie Santistevan; Larissa May
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

2.  Finding the niche: An interprofessional approach to defining oritavancin use criteria in the emergency department.

Authors:  Jared Baxa; Erin McCreary; Lucas Schulz; Michael Pulia
Journal:  Am J Emerg Med       Date:  2019-09-12       Impact factor: 2.469

3.  Developing a Model of Care for Home Infusions of Natalizumab for People With Multiple Sclerosis.

Authors:  Timothy J Schultz; Anne Thomas; Paul Georgiou; Lynette Cusack; Mahasen Juaton; Lorraine Simon; Kerisha Naidoo; Kevin Webb; Jonathan Karnon; Janakan Ravindran
Journal:  J Infus Nurs       Date:  2019 Nov/Dec

4.  Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics.

Authors:  Christian Eckmann; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790

5.  [Rare etiology of a perinephric abscess].

Authors:  Victoria Margaux Krieg; Vanessa Brandes; Christoph Lindemann; Friedrich H Moll; Joachim Leißner
Journal:  Urologie       Date:  2022-04-11

6.  Home infusions of natalizumab for people with multiple sclerosis: a pilot randomised crossover trial.

Authors:  Timothy J Schultz; Anne Thomas; Paul Georgiou; Mahasen S Juaton; Lynette Cusack; Lorraine Simon; Kerisha Naidoo; Kevin Webb; Jonathan Karnon; Janakan Ravindran
Journal:  Ann Clin Transl Neurol       Date:  2021-07-21       Impact factor: 4.511

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.